Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Naval Daver, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Harry Pan, Guan Xing, Yang Pan, Giri Ramsingh

Blood (2022) 140 (Supplement 1): 1445–1446.

https://doi.org/10.1182/blood-2022-170298

Published: 2022

Journal Articles

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Mark Crowther, MD, Genmin Lu, PhD, Janet M. Leeds, PhD, Joyce Lin, BS, Pamela B. Conley, PhD, Alexander Gold, MD, Stuart J. Connolly, MD, John T. Curnutte, MD PhD

Blood (2016) 128 (22): 143.

https://doi.org/10.1182/blood.V128.22.143.143

Published: 2016

Journal Articles

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 3831.

https://doi.org/10.1182/blood.V128.22.3831.3831

Published: 2016

Journal Articles

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2015) 126 (23): 2329.

https://doi.org/10.1182/blood.V126.23.2329.2329

Published: 2015

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Mark Crowther, MD, Gallia G. Levy, MD PhD, Genmin Lu, PhD, Janet Leeds, PhD, Joyce Lin, BS, Pratikhya Pratikhya, MS, Pamela B. Conley, PhD, Stuart Connolly, MD, John T. Curnutte, MDPhD

Blood (2014) 124 (21): 4269.

https://doi.org/10.1182/blood.V124.21.4269.4269

Published: 2014

NARROW

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only